EP. 7: Data From the L-MIND TrialAugust 2nd 2021
Greg Nowakowski, MD [Mayo Clinic, Rochester, Minnesota], reviews the data from the L-MIND trial of tafasitamab and lenalidomide for transplant-ineligible patients with R/R DLBCL (relapsed/refractory diffuse large B-cell lymphoma).
EP. 8: DLBCL: Approaches to Treating Patients Ineligible for TransplantAugust 2nd 2021
Key opinion leaders highlight treatment approaches for patients with DLBCL (diffuse large B-cell lymphoma) who are ineligible for transplant.
EP. 9: Newer Approvals for Previously Treated DLBCLAugust 9th 2021
A panel of experts review the FDA approvals of loncastuximab tesirine and selinexor for the treatment of DLBCL in patients who have received at least 2 prior therapies.
EP. 11: Evaluating CAR T Therapies in LymphomaAugust 16th 2021
A panel of experts explain the differences among the multiple trial designs, patient populations, and CAR T constructs used for treatment of non-Hodgkin lymphoma.